このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Grifols マネジメント

マネジメント基準チェック /24

Grifols'の CEO はNacho Abia Buenacheで、 Apr2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.014%を直接所有しており、その価値は$ 811.88K 。経営陣と取締役会の平均在任期間はそれぞれ6.4年と8.6年です。

主要情報

Nacho Abia Buenache

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.01%
経営陣の平均在職期間	6.7yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Nacho Abia Buenache (56 yo)

less than a year

在職期間

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Thomas Glanzmann	Executive Chairman	18.4yrs	€1.90m	0.029% € 1.9m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	データなし	0.014% € 907.4k
Alfredo Guerra	CFO & VP	17.7yrs	データなし	データなし
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	データなし	データなし
Nuria Lapeña	VP of Corporate Treasury	no data	データなし	データなし
David Bell	Chief Corporate Development	21.7yrs	データなし	0.0029% € 195.3k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.7yrs	データなし	0.00078% € 51.8k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	データなし	データなし
Vicente Blanquer Torre	Chief Quality Officer	31.7yrs	データなし	0.0066% € 437.8k
Sergio Adell	President of Commercial Tech Support	5.7yrs	データなし	データなし
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.016% € 1.1m
Miguel Montblanch	President of Commercial Operations Support	12.7yrs	データなし	データなし

6.7yrs

平均在職期間

59.5yo

平均年齢

経験豊富な経営陣: GIFO.Fの経営陣は経験豊富で経験豊富です（平均在職期間は6.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Thomas Glanzmann	Executive Chairman	18.4yrs	€1.90m	0.029% € 1.9m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	データなし	0.014% € 907.4k
Víctor Grifols Deu	Executive Director	8.3yrs	€1.04m	0.016% € 1.1m
Iñigo Mardones	Independent Director	9.3yrs	€150.00k	データなし
Juan Twose Roura	Member of the Advisory Committee	9.7yrs	€380.00k	データなし
Raimon Grifols Roura	Vice-Chairman	9.3yrs	€1.04m	0.0060% € 401.9k
Tomas Daga Gelabert	Independent External Director	24.4yrs	データなし	0.045% € 3.0m
Albert Coma-Cros	Proprietary Director	less than a year	データなし	0.0097% € 645.0k
Enriqueta Font	Independent Director	5.3yrs	€125.00k	データなし
Montserrat Abellana	Lead Independent Director	2.3yrs	€63.00k	データなし
Susana Gonzalez Rodriguez	Independent Director	2.3yrs	€63.00k	データなし
Anne-Catherine Berner	Independent Director	less than a year	データなし	データなし

6.8yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: GIFO.Fの取締役会は経験豊富であると考えられます ( 8.6年の平均在任期間)。

Grifols マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Recent updates

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24